Bio-Rad Laboratories Inc (BIO)

NYSE


	Symbol		Exchange		Currency
	BIO		NYSE		USD	Real-time
	BIOb		NYSE		USD	Real-time

Currency in USD

BIO Pro Research

345.60

+20.10(+6.18%)

Closed07:59:59

After Hours

340.00-5.60(-1.62%)

11:43:46

Fair Value

Day's Range

324.83

347.80

52 wk Range

262.12

387.99

BIO Income Statement

Featured here, the Income Statement (earnings report) for Bio-Rad Laboratories Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

2,311.66

2,545.63

2,922.55

2,802.25

2,671.26

Total Revenues Growth

+0.97%

+10.12%

+14.81%

-4.12%

-4.67%

Cost Of Revenues

1,054.66

1,107.74

1,259.45

1,233.82

1,240.42

Gross Profit

1,257

1,437.89

1,663.1

1,568.43

1,430.85

Gross Profit Growth

+2.42%

+14.39%

+15.66%

-5.69%

-8.77%

Gross Profit Margin %

54.38%

56.48%

56.91%

55.97%

53.56%

Other Operating Expenses, Total

1,027.34

1,016.56

1,098.36

1,081.61

1,065.15

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-0.64%	-1.05%	+8.05%	-1.52%	-1.52%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	202.71	217.76	247.34	256.79	240.93
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	824.63	798.8	851.02	824.83	824.22
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-

Operating Income

229.66

421.33

564.74

486.82

365.7

Operating Income Growth

+18.83%

+83.46%

+34.04%

-13.8%

-24.88%

EBIT Margin %

9.93%

16.55%

19.32%

17.37%

13.69%

Net Interest Expenses

7.08

-3.66

17.35

19.89

51.46

Net Interest Expenses Growth

+168.54%

-151.68%

+573.89%

+14.62%

+158.78%

Interest Expense, Total

-23.42

-21.86

-1.55

-38.11

-49.44

Interest And Investment Income

30.5

18.2

18.9

58

100.9

Other Non Operating Expenses, Total

-2.35

-3.58

-2.08

-5.02

12.19

EBT, Excl. Unusual Items

234.39

414.08

580.01

501.68

429.35

Gain (Loss) On Sale Of Assets

-

11.7

-

1.4

-

Other Unusual Items, Total

-

-

-

-

-

EBT, Incl. Unusual Items

2,261.08

4,918.01

5,449.06

-4,704.27

-850.1

EBT, Incl. Unusual Items Growth

+341.05%

+117.51%

+10.8%

-186.33%

+81.93%

EBT, Incl. Unusual Items Margin

97.81%

193.19%

186.45%

-167.87%

-31.82%

Income Tax Expense

502.41

1,103.78

1,194.8

-1,076.74

-212.78

Net Income to Company

1,758.68

3,814.23

4,254.26

-3,627.54

-637.32

Minority Interest

-

-

-

-

-

Net Income

1,758.68

3,814.23

4,254.26

-3,627.54

-637.32

Net Income Growth

+381.02%

+116.88%

+11.54%

-185.27%

+82.43%

Net Income Margin %

76.08%

149.83%

145.57%

-129.45%

-23.86%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

1,758.68

3,814.23

4,254.26

-3,627.54

-637.32

Basic EPS - Continuing Operations

58.93

128.13

142.61

-121.79

-21.82

Basic EPS - Continuing Operations Growth

+380.91%

+117.43%

+11.3%

-185.4%

+82.08%

Diluted EPS - Continuing Operations

58.27

126.47

140.83

-121.79

-21.82

Diluted EPS - Continuing Operations Growth

+381.57%

+117.04%

+11.35%

-186.48%

+82.08%

Basic Weighted Average Shares Outstanding

29.84

29.77

29.83

29.79

29.21

Diluted Weighted Average Shares Outstanding

30.18

30.16

30.21

29.79

29.21

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

363.86

559.93

702.34

624.12

511.6

EBITDA Growth

+9.8%

+53.88%

+25.43%

-11.14%

-18.03%

EBITDA Margin %

15.74%

22%

24.03%

22.27%

19.15%

EBIT